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ABSTRACT Site-specific mutagenesis was used to replace
an alanine with a lysine residue and to create a deletion of seven
amino acids into the first transmembrane region (TMI region)
of the aspartate chemoreceptor in Escherichia coli. The muta-
tions resulted in the loss of aspartate chemotaxis on tryptone
motility plates. However, both mutant proteins were able to
associate with the membrane and to bind aspartate. They were
both refractory to methylation or to modification of the
C-terminal region of the protein by the cheB gene product.
These results suggested that the integrity of the TMI domain of
the protein was required to maintain the function of the
cytoplasmic portion of the receptor. The Lys-19 mutant re-
tained the ability to generate a repellent response. Analysis of
suppressor mutations of the Lys-19 mutation suggested that
formation of an ion pair or specific changes in a 40 amino acid
stretch in the cytoplasmic region of the protein (from amino
acid 264 to amino acid 303) could suppress the effects of the
Lys-19 mutation. The TMI region of the protein may be
involved in transmembrane transmission of signals from the
periplasmic portion of the cell to the cytoplasmic portion of the
Tar protein.
The signal transducers for bacterial chemotaxis are
transmembrane proteins. The genes encoding five different
bacterial receptor-transducer proteips were cloned, the ami-
no acid sequences of the gene products were deduced from
the nucleic acid sequences (1-4), and one of the trans-
membrane proteins was isolated in homogeneous form (5).
On the basis of these data, it has been suggested that the
chemotaxis signal transducing proteins are composed of a
series of differentiated functional and structural domains.
These include a periplasmic component involved in ligand
binding, a transmembrane segment, and a cytoplasmic do-
main required for signal transduction. Fig. 1 shows the
distribution of these domains along the linear amino acid
sequence of the tar gene product.
The Tar protein is the chemoreceptor responsible for
binding aspartate and regulating the cells' response to envi-
ronmental changes in concentrations of aspartate, a number
of related amino acids, and maltose (6). The Tar protein also
controls responses to repellents, such as nickel ion and
glycerol (6, 14). Its sequence includes two stretches of
hydrophobic amino acids that have been called the first and
second transmembrane regions (TMI and TMII) (Fig. 1). The
hydrophobic stretch including amino acids 7-37 constitutes a
"signal sequence" that apparently is not processed and
remains a part of the mature protein (3). The second se-
quence, TMII, is thought to traverse the membrane and
function in the assembly of the rest of the protein into the
cytoplasmic space. The regions labeled K1 and R1 (Fig. 1)
indicate portions of the protein that include specific sites that
are modified by reversible methylation (7-9). The periplasmic
portion of the protein is thought to include the ligand binding
site. Information is transmitted across the membrane in
response to changes in aspartate binding, resulting in
methylation or demethylation at the K1 and R1 sites. A
second process is also initiated, which results in the gener-
ation of a signal that informs the flagellar motor of changes in
ligand concentration as a function of time at the surface of the
cell. To more clearly delineate the functions of the structural
domains of the Tar transmembrane protein, we have initiated
a series of studies involving site-specific mutagenesis. In this
paper, we describe and characterize two mutations in the
TMI region. The first involves a deletion of seven amino
acids. The second involves the introduction of a potentially
charged amino acid residue in the middle of the hydrophobic
region. Our results suggest that the TMI region may play a
role in the assembly and maintenance of the structure of the
protein and mediate its transmembrane signaling function.
MATERIALS AND METHODS
Strains and Vectors. Escherichia coli strains used in this
work were RP4372 recA [tsr-i A(tar-tap) 5201] (8), HB294
recA [tsr::TnS A (tar-cheB)], and JM103 (10). All plasmids
were derivatives of pAK101 (8). M13 mplO for site-specific
mutagenesis and M13 mpl8 and M13 mpl9 forDNA sequenc-
ing were purchased from Pharmacia. The DNA encoding Tar
was inserted into the EcoRI site of Xgtll (11); the phage was
used for transduction of tar and for the construction of strains
carrying tar in single copy.
Media and Chemicals. Tryptone broth contained 1%
Bactotryptone (Difco) and 0.5% NaCl. Tryptone motility
plates contained 0.25% Bactoagar (Difco) in tryptone broth.
Restriction enzymes were purchased from Bethesda Re-
search Laboratories, Boehringer Mannheim, or New En-
gland Biolabs. L-[methyl-3H]Methionine (15.0 Ci/mmol; 1 Ci
= 37 GBq) was purchased from ICN and L-[U-14C]aspartic
acid (224 mCi/mmol) was from Amersham.
Methods. The oligonucleotides for site-specific mutagene-
sis shown in Fig. 2 were chemically synthesized on an
Applied Biosystems oligonucleotide synthesizer by Suzanna
Horvath of the California Institute of Technology. Muta-
genesis was performed according to Newman et al. (12).
After the mutations were verified by sequencing, the
EcoRI-Xba I fragment carrying the mutation was inserted
into the tar gene on pAK101. To select pseudorevertants,
RP4372 recA carrying pAK101 with either the Lys-19 muta-
tion or the deletion was inoculated into tryptone motility
plates. After 24 hr, "flares" emerged from the initial
inoculum; one or two of these were picked from each plate.
The DNA was isolated and retransformed at low concentra-
tion into RP4372 recA. "Swarmers" were picked and DNA
was isolated from these strains. The strategy for mapping
Abbreviation: TMI and TMII, first and second transmembrane
regions.
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FIG. 1. Structure of the Tar protein. The Tar protein has 553 amino acid residues. TMI refers to the region between amino acid residues
7 and 37 and TMII includes amino acids 189-212. The K1 and R1 regions include the sites that are methylated and demethylated by
methyltransferase (CheR) and methylesterase (CheB).
mutations, for DNA sequencing, and for 3H-methyl labeling
of Tar protein was basically the same as described (13).
The procedure for the separation of cytoplasm and mem-
brane was as follows. Cells were grown at 30'C in T broth to
OD590 = 0.6-0.8, washed with motility buffer (10 mM
potassium phosphate buffer, pH 7.0/0.1 mM EDTA/10 mM
sodium lactate) twice, and sonicated for 3 min on ice. Whole
cells were removed by centrifugation at 5000 x g for 5 min at
40C. The membrane fraction was separated from cytoplasm
by centrifugation at 100,000 x g for 30 min at 40C.
The procedure for measuring the dissociation constant (Kd)
of L-aspartate from Tar was described by Clarke and
Koshland (15). The tethered cell assay was performed as
described (8).
RESULTS
Site-Specific Mutagenesis. Fig. 2 describes the oligonucle-
otides that were prepared to introduce mutations into the
TMI region. The first mutation involved the substitution of a
lysine at position 19 for an existing alanine residue. The
change was affected by introducing a thymine and two
adenine residues. This resulted in a change of Ala-19 to a
lysine and in the formation ofaDra I restriction endonuclease
digestion site. The deletion was prepared by using an oligo-
nucleotide with 15 base pairs of homology on either side of
the region to be deleted (Fig. 2). The deletion resulted in the
removal of a stretch ofamino acids from Val-7 to Met-13. The
cloned DNA that carried the mutations was sequenced after
introduction into the plasmid pAK101 and the plasmid was
subsequently introduced into E. coli RP4372 recA. This strain
is deleted for two chemoreceptors, tar and tap, and has a
small deletion in the tsr receptor (16). The only intact
receptor protein in this strain is the product of the trg gene,
and this does not affect the behavior of the cells on tryptone
motility plates. In subsequent experiments, a further muta-
tion eliminating trg was introduced without perceptibly
changing the results. Fig. 3 shows that the deletion and the
introduction of a lysine residue result in the absence of
chemotaxis behavior on tryptone motility plates.
Membrane Assembly of Mutant Proteins. To test for the
association of the mutated gene products with the membrane,
cells (RP4372 recA with or without pAK101, pAK101 Lys-19,
or pAK101A7-13) were grown and fractionated into mem-
brane and cytoplasm, and the components of each were
separated by electrophoresis and tested for the ability to react
with Tar-specific antibodies (13). Fig. 4A shows that the Tar
protein is associated, almost entirely, with the membrane
fraction. The same general distribution is found for the
deletion mutant and for the Lys-19 mutant. The mobility of
the Lys-19 gene product is slightly greater than that of the
wild type or the deletion.
Although these data indicate that the mutant and the
wild-type proteins associate with the membrane fraction, it is
possible that they may have been incorrectly assembled into
the membrane. To test for the integrity of the N-terminal
portion of the Tar protein, the ability to bind aspartate was
measured. The Kd determined for the wild-type aspartate
receptor was similar to that described (15)-i.e., 11 AM-
whereas that for the Lys-19 mutant was 25 AM and that for
the 7 amino acid deletion was 14 MM. These results suggest
that the mutant proteins were able to assemble and form the
appropriate ligand binding site. Furthermore, behavioral
studies were undertaken to test for residual responses to
A. ala-19 * lys-19
Wild type amino acid sequence
nucleotide sequence
Oliqonucleotide sequence
Mutant nucleotide sequence
amino acid sequence
15
leu gly val phe
CTG GGG GTA TTC
22
ala leu leu gin
GCA CTG TTA CAG
31 GAC CCC CAT AAA TTT GAC AAT GTC 5'
CTG GGG GTA ITT AAA CTG TTA CAG
leu gly val phe lys leu leu gin
B. deletion val-7 to met-13
Wild type amino acid sequence
nucleotide sequence
Oligonucleotide sequence
Mutant nucleotide sequence
amino acid sequence
2
ile asn arg ile
ATT AAC CGT ATC
18
arq val val thr leu leu val met val leu gly val phe
CGC GTA GTC ACG CTG TTG GTA ATG GTG CTG GGG GTA TTC
3' TAA TTG GCA TAG GCG
ATT AAC CGT ATC CGC
ile asn arg ile arg
CAC GAC CCC CAT AAG 5'
GTG CTG GGG GTA TTG
val leu gly val phe
FIG. 2. Oligonucleotides used for site-specific mutagenesis. (A) The oligonucleotide used to introduce lysine to replace Ala-19 was made
of 24 nucleotides and also introduced a new restriction site for Dra I as well as the lysine codon at position 19. (B) The oligonucleotide used
in making the deletion from Val-7 to Met-12 was 30 nucleotides long.
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FIG. 3. Chemotaxis of strains carrying mutant genes. The cells were inoculated into tryptone motility agar. (a) RP4372 recA without plasmid.
(b) RP4372 recA with pAK101. (c) RP4372 recA with pAK101 carrying the mutation Lys-19. (d) RP4372 recA with pAK101 carrying a deletion
from Val-7 to Met-13.
A 2 4 5 t-.
B
FIG. 4. Detection of the Tar protein by immunoblotting. (A)
Localization of mutant Tar protein. The membrane fraction was
separated from the cytoplasmic fraction after sonication by centrif-
ugation. The Tar protein was detected by immunoblotting with
anti-Tar antiserum. The lower band in the lanes that include
membrane-derived protein is the result of the crossreaction of our
antibody with a non-Tar derived protein. Lanes 1 and 2, RP4372 recA
with pAK101; lanes 3 and 4, RP4372 recA with pAK101 carrying the
Lys-19 mutation; lanes 5 and 6, RP4372 recA with pAK101 carrying
the deletion from Val-7 to Met-13; lane 7, RP4372 recA without
plasmid; lanes 1, 3, 5, and 7 represent the membrane fraction; lanes
2, 4, and 6 represent the cytoplasmic fraction. (B) Effects of
modification of the Tar protein by the CheR and CheB proteins.
Lanes 1, the host cell was RP4372 recA (cheR+, cheB+); lanes 2, the
host cell was HB294 recA (cheR-, cheB-).
aspartate. The deletion showed no attractant response upon
the addition of aspartate to tethered cells. The attractant
response of the Lys-19 mutant was difficult to test since it
showed only counterclockwise rotation when tethered. How-
ever, when aspartate was washed away, the Lys-19 mutant
showed an immediate transient repellent response. Taken
together, these data suggest that the ligand binding region of
the mutant gene products is able to function in a manner
similar to the wild-type protein. Furthermore, the Lys-19
mutant is able to initiate a repellent response.
To further test the properties of the mutant gene products,
we looked for functions that are controlled by the cytoplas-
mic portion of the molecule. Neither the Lys-19 mutant nor
the deletion mutant product were found to be methylated
under ordinary growth conditions. It is known (17, 22) that
the Tar protein undergoes modification catalyzed by the
product of the cheB gene. This results in the specific
deamination of glutamine residues in the K1 and R1 domains
of the protein. To determine if the cytoplasmic portions of the
mutant proteins were still subject to modification, they were
compared in background strains that were proficient for cheB
modification and cheR-mediated methylation and in other
strains that lacked the cheR and cheB gene functions. Fig. 4B
shows that the wild-type polypeptide is modified in its
mobility in the cheR, cheB background strains, whereas the
mobility of the Lys-19 and of the deletion gene product is
exactly the same in both backgrounds. This suggests that the
mutant polypeptides are not good substrates for modification
by the cheB gene product. Thus, the structure of the
C-terminal portion of the molecule may be distorted in the
mutants so that it no longer can be recognized by the
modification enzymes.
Isolation of Pseudorevertants. Pseudorevertants were se-
lected on tryptone motility plates. After incubation for 24 hr,
swarms emerged from an initial inoculum of the mutant
strain. To determine the nature of the pseudorevertants,
DNA was extracted and used to transform RP4372 recA; a
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cloned transformant was subsequently retested for chemo-
taxis. To map the suppressor mutations, a number of tech-
niques were used. Since the Lys-19 mutation had an extra
Dra I site, nucleotide changes at that position resulted in
changes in the Dra I restriction pattern. Second, the gene was
subdivided into three segments by using the restriction
enzymes Xba I, Kpn I, and Nsi I. Each of these fragments
was tested for the presence of suppressor activity by rein-
sertion into a mutant plasmid. Once the suppressor was
localized, the segment carrying the suppressor was se-
quenced and the exact nature of the mutation was deter-
mined.
We found no suppressors that mapped within the tar gene
that changed the phenotype of the deletion mutation. On the
other hand, a large number of pseudorevertants were found
for the Lys-19 mutation. Thirty-five ofthese were sequenced.
The results are tabulated in Fig. 5 and illustrated graphically
in Fig. 6. The suppressors were found to be localized in three
regions of the molecule. Seven ofthem were found in the TMI
region. These included six same-site revertants where the
Lys-19 residue was found to be changed to a relatively
hydrophobic amino acid, glutamine, isoleucine, or threonine.
No changes to charged amino acids were found at this site.
A pseudorevertant in the TMI region was found to be the
result of mutation of Val-17 to Glu-17. This suggests that
opposite charged residues might form ion pairs and thus
suppress the effects of the Lys-19 mutation. The second
cluster of suppressors was found in TMII. They included five
suppressor mutations-three of them resulting in changes of
a hydrophobic amino acid to a glutamate residue, again
suggesting that one mechanism of suppression may be the
formation of an ion pair in the membrane. Most of the
suppressor mutations were found in the region of the mole-
cule between amino acids 264 and 303. Many of these were
found multiple times. Thus, for example, Gly-271 was found
to be changed to alanine, cysteine, serine, or valine. Fur-
thermore, Thr-279 was found in five separate instances to be
changed to Ile-279.
A. Wild type
GCA ala-19
Mutant
AAA lys-19
FIG. 6. Distribution of suppressor mutations of Lys-19 mutation.
The cartoon represents the distribution of the Tar polypeptide chain
in the periplasmic, membrane, and cytoplasmic regions of the cell.
One-letter codes for amino acid residues are A for alanine, C for
Revertant No. cysteine, D for aspartic acid, E for glutamic acid, G for glycine, H
for histidine, I for isoleucine, K for lysine, L for leucine, R for
CAA gln-19 2 arginine, S for serine, T for threonine, V for valine, and W for
ATA ile-19 1 tryptophan. The numbers in parentheses represent amino acid
ACA thr-19 3 residues numbered from the N-terminal end.
B. Wild type
GTA val-17
TGG trp-192
GCG ala-198
GTC val-201
GTA val-202
ACC thr-264
CAT his-267
GGT
GGC
GGT
GGT
GGT
ACC
GAA
GAT
gly-271
gly-271
gly-271
gly-271
gly-278
thr-279
glu-281
asp-288
GAT asp-288
ACT thr-293
ACT thr-303
Suppressor
GAA glu-17
CGG arg-192
GAG glu-198
GAG glu-201
TTA leu-202
ATC ile-264
GAT asp-267
GCT ala-271
TGT cys-271
AGT ser-271
GTT val-271
GCT ala-278
ATC ile-279
AAA lys-281
GCT ala-288
GTT val-288
ATT ile-293
ATT ile-303
No. To test for effects of gene dosage on suppression, some of
the suppressor mutations were moved onto bacteriophage X
and introduced into the cells as single copy genes. They were
found to permit complete chemotaxis function. The suppres-
1 sors were also tested for their ability to be modified and
2 methylated. All of them showed methylation and CheR-,
1 CheB-mediated modification (data not shown). Finally, a
3 number of the suppressors, particularly those in the
transmembrane region and the C-terminal portion of the
molecule, were separated by in vitro recombination from the
1 original Lys-19 mutation and tested for their ability to
3 mediate chemotaxis. Most of the suppressor mutations were
1 themselves found to be functional (data not shown).
1
5
2
2
FIG. 5. Revertants and suppressors of the Lys-19 mutation.
DISCUSSION
The results of introducing a potentially charged amino acid or
a relatively large deletion in the TMI region suggest that it
plays multiple roles in the function of the receptor. A portion
of TMI may be important for the insertion of the protein into
the membrane (N. Mutoh and M.S., unpublished data). In
addition, TMI appears to play a role in maintaining the
function and structure of the C-terminal portion of the
receptor molecule. The deletion of seven amino acids from
the start of the TMI region or the introduction of a lysine
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residue into the middle of TMI does not effectively change
the association of the protein with the membrane. The
mutations, however, result in the loss of chemotaxis func-
tion, which is accompanied by a distortion in the structure of
the cytoplasmic part of the receptor so that it no longer
functions as a substrate for modification or methylation.
Some form of transmembrane signaling is still possible with
the Lys-19 mutant. It responds to some repellents and to the
removal of aspartate; however, it does not show any re-
sponse to attractants. Studies by Bogonez and Koshland (18)
of the solubilized Tar receptor protein showed that in the
absence of high concentrations of glycerol and appropriate
lipids, the purified receptor was not able to act as a substrate
for methylation; thus, the appropriate stabilization of the
transmembrane region may be required for the integrity ofthe
C-terminal portion of the protein.
The introduction of a lysine residue into the transmem-
brane region could require alterations in TMI structure to
accommodate the presence of a charge in the membrane.
These changes, for example, could result from the associa-
tion of the y-amino group of Lys-19 with head groups of the
phospholipids in the membrane, distorting the structure of
the TMI region and thus affecting the C-terminal region of the
molecule or the ability of the molecule to assemble into the
correct oligomeric form. If this notion is correct, then we
would predict that the Lys-19 mutation could be suppressed
in a number of ways. One type of suppression would result
from the formation of an ion pair that would be more stable
than a single charge in the hydrophobic context of the
membrane. The suppressors that map in the TMII region
suggest that the two transmembrane regions are closely
associated so that nearby amino acid residues that form
glutamate moieties could pair with Lys-19 (see Fig. 6). The
finding that most ofthe suppressors cluster in the cytoplasmic
portion of the protein-i.e., between amino acids 264 and
303-can be rationalized if this portion of the molecule were
intimately associated with part of the TMI sequence or the
membrane adjacent to the TMI sequence. Changes in struc-
ture in the region between amino acids 264 and 303 could
compensate for conformational changes introduced by the
presence of the Lys-19 mutation. A portion of the C terminus
of the Tar molecule may interact with TMI and thus act as a
functional link between the transmembrane region and the
signaling region. TMI may play a specific role in the
transmembrane transmission of signals and in generating a
cytoplasmic response to ligand binding events that occur in
the periplasmic space.
It is clear that changes in the structure of the transmem-
brane region-i.e., deletions or the introduction of potential-
ly charged residues-can have marked effects on the signal-
ing function of the chemotaxis transmembrane protein. There
have been a number of other examples of mutations resulting
in charged residues that are stabilized in the transmembrane
portion of specific proteins (19, 20). Most recently, a variant
of a transmembrane receptor with a glutamate residue in a
portion of the molecule that is thought to traverse the
membrane was found to have oncogenic properties (21). One
interpretation of these results is that the charged residue
distorted the structure of the transmembrane protein and
fixed the protein in a signaling mode. In much the same way,
the Lys-19 mutation results in a protein that is defective in
signaling. It is capable of signaling the presence of repellent
stimuli but is insensitive to attractants. The bacterial
chemotaxis receptors provide an interesting model system
whereby the extensive tools of molecular genetics can be
applied to questions of the mechanisms of signal transduc-
tion.
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